360 related articles for article (PubMed ID: 24071011)
41. Immunohistochemical staining characteristics of nephrogenic adenoma using the PIN-4 cocktail (p63, AMACR, and CK903) and GATA-3.
McDaniel AS; Chinnaiyan AM; Siddiqui J; McKenney JK; Mehra R
Am J Surg Pathol; 2014 Dec; 38(12):1664-71. PubMed ID: 24921643
[TBL] [Abstract][Full Text] [Related]
42. GATA3 immunohistochemical expression in invasive urothelial carcinoma.
Mohammed KH; Siddiqui MT; Cohen C
Urol Oncol; 2016 Oct; 34(10):432.e9-432.e13. PubMed ID: 27241168
[TBL] [Abstract][Full Text] [Related]
43. Expression of PAX8 in nephrogenic adenoma and clear cell adenocarcinoma of the lower urinary tract: evidence of related histogenesis?
Tong GX; Weeden EM; Hamele-Bena D; Huan Y; Unger P; Memeo L; O'Toole K
Am J Surg Pathol; 2008 Sep; 32(9):1380-7. PubMed ID: 18670350
[TBL] [Abstract][Full Text] [Related]
44. Programmed Death-ligand 1 Expression in Upper Tract Urothelial Carcinoma.
Skala SL; Liu TY; Udager AM; Weizer AZ; Montgomery JS; Palapattu GS; Siddiqui J; Cao X; Fields K; Abugharib AE; Soliman M; Hafez KS; Miller D; Lee CT; Alva A; Chinnaiyan AM; Morgan TM; Spratt DE; Jiang H; Mehra R
Eur Urol Focus; 2017 Oct; 3(4-5):502-509. PubMed ID: 28753826
[TBL] [Abstract][Full Text] [Related]
45. Heterarchy of transcription factors driving basal and luminal cell phenotypes in human urothelium.
Fishwick C; Higgins J; Percival-Alwyn L; Hustler A; Pearson J; Bastkowski S; Moxon S; Swarbreck D; Greenman CD; Southgate J
Cell Death Differ; 2017 May; 24(5):809-818. PubMed ID: 28282036
[TBL] [Abstract][Full Text] [Related]
46. Do HOXB13 and P63 have a role in differentiating poorly differentiated prostatic carcinoma from urothelial high-grade carcinoma?
Alshenawy HA; Saied E
APMIS; 2015 Sep; 123(9):772-8. PubMed ID: 26200506
[TBL] [Abstract][Full Text] [Related]
47. Insulin-like growth factor-1 receptor expression in upper tract urothelial carcinoma.
Eich ML; Tregnago AC; Faraj SF; Palsgrove DN; Fujita K; Bezerra SM; Munari E; Sharma R; Chaux A; Netto GJ
Virchows Arch; 2019 Jan; 474(1):21-27. PubMed ID: 30338346
[TBL] [Abstract][Full Text] [Related]
48. Is GATA3 expression maintained in regional metastases?: a study of paired primary and metastatic urothelial carcinomas.
Zhao L; Antic T; Witten D; Paner GP; Taxy JB; Husain A; Gwin K; Mirza MK; Lingen MW; Tretiakova MS
Am J Surg Pathol; 2013 Dec; 37(12):1876-81. PubMed ID: 24121175
[TBL] [Abstract][Full Text] [Related]
49. Expression of PAX8 in normal and neoplastic tissues: a comprehensive immunohistochemical study.
Tacha D; Zhou D; Cheng L
Appl Immunohistochem Mol Morphol; 2011 Jul; 19(4):293-9. PubMed ID: 21285870
[TBL] [Abstract][Full Text] [Related]
50. Sporadic renal hemangioblastoma with CA9, PAX2 and PAX8 expression: diagnostic pitfall in the differential diagnosis from clear cell renal cell carcinoma.
Kuroda N; Agatsuma Y; Tamura M; Martinek P; Hes O; Michal M
Int J Clin Exp Pathol; 2015; 8(2):2131-8. PubMed ID: 25973115
[TBL] [Abstract][Full Text] [Related]
51. Diagnostic utility of p63/P501S double sequential immunohistochemical staining in differentiating urothelial carcinoma from prostate carcinoma.
Srinivasan M; Parwani AV
Diagn Pathol; 2011 Jul; 6():67. PubMed ID: 21777423
[TBL] [Abstract][Full Text] [Related]
52. PAX8 positivity in nested variant of urothelial carcinoma: a potential diagnostic pitfall.
Legesse T; Matoso A; Epstein JI
Hum Pathol; 2019 Dec; 94():11-15. PubMed ID: 31669177
[TBL] [Abstract][Full Text] [Related]
53. Molecular aspects of upper tract urothelial carcinoma.
Patel N; Arya M; Muneer A; Powles T; Sullivan M; Hines J; Kelly J
Urol Oncol; 2014 Jan; 32(1):28.e11-20. PubMed ID: 23428541
[TBL] [Abstract][Full Text] [Related]
54. GATA3: a promising marker for metastatic breast carcinoma in serous effusion specimens.
Shield PW; Papadimos DJ; Walsh MD
Cancer Cytopathol; 2014 Apr; 122(4):307-12. PubMed ID: 24421220
[TBL] [Abstract][Full Text] [Related]
55. The Utility of GATA3 in the Diagnosis of Urothelial Carcinomas With Variant Morphologic Patterns.
Verduin L; Mentrikoski MJ; Heitz CT; Wick MR
Appl Immunohistochem Mol Morphol; 2016 Aug; 24(7):509-13. PubMed ID: 26317312
[TBL] [Abstract][Full Text] [Related]
56. Differential diagnosis of bladder versus colorectal adenocarcinoma: keratin 7 and GATA3 positivity in nuclear ß-catenin-negative glandular tumours defines adenocarcinoma of the bladder.
Broede A; Oll M; Maurer A; Siegert S; Stoerkel S; Golz R; Schwamborn K; Veeck J; Knuechel R; Gaisa NT;
J Clin Pathol; 2016 Apr; 69(4):307-12. PubMed ID: 26463756
[TBL] [Abstract][Full Text] [Related]
57. Prospective analysis of Ki-67 as an independent predictor of oncologic outcomes in patients with high grade upper tract urothelial carcinoma.
Krabbe LM; Bagrodia A; Lotan Y; Gayed BA; Darwish OM; Youssef RF; John G; Harrow B; Jacobs C; Gaitonde M; Sagalowsky AI; Shariat SF; Kapur P; Margulis V
J Urol; 2014 Jan; 191(1):28-34. PubMed ID: 23871758
[TBL] [Abstract][Full Text] [Related]
58. Upper urinary tract urothelial carcinoma and its variants: transition from morphology to personalized molecular characterization in diagnosis, prognosis, and therapy.
Cimadamore A; Scarpelli M; Santoni M; Cheng L; Lopez-Beltran A; Montironi R
Expert Rev Mol Diagn; 2018 Dec; 18(12):1021-1028. PubMed ID: 30452305
[TBL] [Abstract][Full Text] [Related]
59. PAX2 and PAX8: useful markers for metastatic effusions.
Waters L; Crumley S; Truong L; Mody D; Coffey D
Acta Cytol; 2014; 58(1):60-6. PubMed ID: 24334997
[TBL] [Abstract][Full Text] [Related]
60. Enhancing upper tract urothelial carcinoma diagnosis: Utility of cytokeratin 17 and CK20/CD44/p53 immunohistochemical panel.
Irwin T; Donlan AW; Owens L; Alvarez R; Vakar-Lopez F; Tretiakova M
Hum Pathol; 2024 Apr; 146():43-48. PubMed ID: 38593961
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
